---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-23-000020"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:56:20.368099+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health FY2022 revenue $8.2M (+20% YoY); Q4 cash burn $7.1M

## Summary
- Full-year revenue $8.2M, up 20% from $6.8M; OvaSuite volume 21,423 units (+23% YoY).
- Gross margin improved to 53% (FY) vs 45% in 2021; Q4 gross margin 57% vs 55%.
- Cash and short-term investments $13.6M at year-end; 2023 cash utilization guided $16-19M.
- OvaWatch launched late 2022; March 2023 coverage secured from major national payer.
- EndoCheck (endometriosis blood test) development on track for 2023 launch target.

## SEC filing metadata
- accession: 0000926617-23-000020
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661723000020/0000926617-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661723000020/awh-20230322x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-23-000020
- JSON: https://secwatch.observer/filing/0000926617-23-000020.json
- Plain text: https://secwatch.observer/filing/0000926617-23-000020.txt

## Key facts
- Earnings Releases
  Aspira Women's Health Inc. reported the three months ended December 31, 2022 results: revenue $2.2 million.
  - Period: the three months ended December 31, 2022
  - Revenue: $2.2 million
  - Result: reported results
  source text: Total revenue for the three months ended December 31, 2022 was $2.2 million, an increase of 16% compared to $1.9 million for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661723000020/0000926617-23-000020-index.htm
- Earnings Releases
  Aspira Women's Health Inc. reported the year ended December 31, 2022 results: revenue $8.2 million.
  - Period: the year ended December 31, 2022
  - Revenue: $8.2 million
  - Result: reported results
  source text: Total revenue was $8.2 million for the year ended December 31, 2022, an increase of 20% compared to $6.8 million for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661723000020/0000926617-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.